HJB - Your Trusted Biologics CDMO Partner

HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB

HJB - Your Trusted Biologics CDMO Partner


Mar, 2022

HJB Congratulates its partner BioneCure for receiving IND approval from U.S.FDA for BIO-106

HJB's experienced team carried out process development, GMP manufacturing, and IND related studies for the antibody part seamlessly to guarantee the success of BIO-106. The team also supported the BIO-106’s IND filing in U.S. BIO-106 is a TROP-2 targeting novel ADC drug which was designed targeting overexpressed TROP-2. Using the unique “Payload” technology, BIO-106 was designed to have better safety and better therapeutic window.

“Congratulations to BioneCure on receiving approval for BI-5 to enter clinical phase. It is our honor to support BioneCure for BI-5’s development, manufacturing, and IND filing. With strong expertise and capabilities to develop and manufacturing innovative biologics, HJB will continue to deliver high quality, reliable, and rapid service which empowering our global partners to accelerate their innovative treatment development.” said Dr. Yang Jerry, General Manager of HJB


Since the operation of the GMP facility in 2018, HJB delivered more than 50 batches of GMP production in 20 CDMO projects for its partners. These projects are in different stages of clinical trials in China and U.S. With 6 drug substance production lines, and 1 drug production filling line, HJB has the capability to provide its partners end to end CMC solutions.

About BioneCure

BioneCure is a clinical stage pharmaceutical company that developing innovative therapeutic for the treatment of cancer. BioeCure have abundant pipelines including multiple antibody drug conjugate (ADC), bi-specific antibodies, and immunomodulators